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Abstract
Objective This review addresses sedation management on paediatric intensive
care units and possible gaps in the knowledge of optimal sedation strategies. We
present an overview of the commonly used sedatives and their pharmacokinetic
and pharmacodynamic considerations in children, as well as the ongoing studies
in this field. Also, sedation guidelines and current sedation strategies and assess-
ment methods are addressed.
Key findings This review shows that evidence and pharmacokinetic data are
scarce, but fortunately, there is an active research scene with promising new PK
and PD data of sedatives in children using new study designs with application of
advanced laboratory methods and modelling. The lack of evidence is increasingly
being recognized by authorities and legislative offices such as the US Food and
Drug Administration (FDA) and European Medicines Agency (EMA).
Conclusion The population in question is very heterogeneous and this overview
can aid clinicians and researchers in moving from practice-based sedation man-
agement towards more evidence- or model-based practice. Still, paediatric seda-
tion management can be improved in other ways than pharmacology only, so
future research should aim on sedation assessment and implementation strategies
of protocolized sedation as well.
Introduction
Sedation management is a crucial element of paediatric
critical care medicine, aiming at reducing children’s anxi-
ety, distress and oxygen demand. Adequate sedation
improves patient–ventilator synchrony and prevents auto-
extubation in ventilated children.[1] Moreover, it allows tol-
erance to diagnostic or therapeutic procedures. However,
sedation induced by pharmacological agents often leads to
adverse events including prolonged mechanical ventilation,
tolerance, withdrawal syndrome and even paediatric delir-
ium. Dosing regimens are not always based on PK data or
paediatric pharmacological research findings, and even
today, more than 80% of drugs used in the paediatric
intensive care unit (PICU) are off-label or unlicensed.[2]
Still, the European Medicines Agency (EMA) and the US
Food and Drug Administration (FDA) have prioritized
paediatric pharmacological research efforts to achieve more
evidence-based pharmacotherapy.[3]
To date, there is no consensus on sedation management
for children.[4,5] This review provides an overview of evi-
dence for the commonly used drugs in paediatric sedation
management and inventories ongoing and future research.
Table 1 presents an overview of prospective observational
studies and randomized controlled trials performed so far.
Sedation Assessment
A ‘gold standard’ tool to assess the sedation state of chil-
dren on intensive care units has not yet been identified.[6]
Assessment is difficult because signs such as motor restless-
ness, agitation and increased muscle tone that may point at
undersedation are also signs of pain. It is generally accepted
that preverbal children are not able to express their pain or
discomfort in a way caregivers understand or interpret as
such. Furthermore, children may suffer from separation
anxiety and fear for strangers and thus show behaviour
indicating undersedation.
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Table 1 An overview of performed pharmacological studies in paediatric intensive care sedation
Study
Sample size
and age Design Outcome
Booker et al.[149] N = 50, 6
months–9 years
Observational cohort study (midazolam bolus
200 mcg/kg followed by CI 120–360 mcg/kg per h)
Adequate sedation, no major
adverse events
Shelly et al.[150] N = 50, 0–18 years Prospective observational cohort study of midazolam CI Adequate sedation, delayed
awakening especially in renal
failure patients
Macnab et al.[151] N = 23, 6
months–6 years
Prospective observational cohort study of a midazolam
loading dose after cardiothoracic surgery
Termination of study after severe
hypotension, other participants
showed no haemodynamic
changes
de Wildt et al.[62] N = 21, 0–17 years Observational cohort PK-PD study with protocolized
sedation strategy: start dose midazolam 0.1 mg/kg
bolus, followed by 100 mcg/kg per h
No clear PK-PD relationship,
adequate sedation reached
with protocol
No report on toxicity
Rigby-Jones et al.[152] N = 26, 0–10 years Observational cohort PK study, remifentanil and midazolam Adequate sedation, 1 patient
showed hypotension
Ambrose et al.[153] N = 30, 0–10 years Three-step: IV clonidine: low dose vs high dose
(variable dose together with midazolam),
3rd group fixed dose
No adverse effects on
haemodynamics, sufficient
sedation in combination with
midazolam
Arenas-Lopez et al.[83] N = 24, 0–5 years Prospective cohort study, oral clonidine
as additive to morphine/lorazepam
Opioid and benzodiazepine
sparing, safe and effective
Wolf et al.[81] N = 129, 0–15 years Double-blind, randomized controlled trial
of IV clonidine vs midazolam
No difference in effectivity,
underpowered due to
recruitment problems
H€unseler et al.[82] N = 219, 0–2 years Double-blind, randomized controlled trial
of IV clonidine vs midazolam
Opioid and benzodiazepine
sparing in neonatal age group
Duffett et al.[84] N = 50, 0–18 years Double-blind, randomized controlled trial of
oral clonidine vs placebo in addition to
physician-driven sedation
No significant difference in
effectivity, study with clonidine
clinically feasible
Su et al.[154] N = 36, 1–24 months Open-label dose–response study of dexmedetomidine Reduction of supplementary
sedatives, no cardiovascular
adverse effects
Hosokawa et al.[155] N = 141, 0–15 years Observational cohort study: dexmedetomidine vs
chlorpromazine, midazolam or fentanyl
in cardiac surgery patients
Comparable efficacy, more
haemodynamic adverse effects
in dexmedetomidine group
Aydogan et al.[88] N = 32, 12–17 years Double-blind, randomized controlled trial of IV
dexmedetomidine vs midazolam in adolescents
after scoliosis surgery
Decreased pain score, fentanyl
consumption and delirium in
dexmedetomidine group,
more bradycardia in
dexmedetomidine group
Diaz et al.[156] N = 10, 0–8 years Observational PK study of dexmedetomidine
for postoperative sedation
Hypotension in most cardiac
surgery patients
Tobias and
Berkenbosch[89]
N = 30, 0–8 years Randomized controlled trial: IV low dose or
high dose, dexmedetomidine vs midazolam
Equivalent sedation across 3
groups, lower heart rate in
dexmedetomidine group: 1
patient removed from the
study after bradycardia
Svensson and
Lindberg[157]
N = 174, 0–16 years Prospective observational cohort study:
propofol CI in the PICU
No occurrence of PRIS
in cohort group
Rigby-Jones et al.[158] N = 21, 0–12 years Observational PK study of propofol CI Adequate sedation in
17 of 20 scored patients, 1 case
of hypotension and metabolic
acidosis
Hartvig et al.[159] N = 10, 8–30 months Observational PK study of ketamine CI
after cardiac surgery
Adequate sedation, no adverse
effects observed
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Roughly, two types of sedation assessment scales are
available[6,7]; those that score a number of behavioural
indicators of distress and those that consist of one item
describing the level of consciousness. Examples of the latter
type validated for children are the University of Michigan
Sedation Scale (UMSS)[8] and the State Behavioral Scale
(SBS).[9] The UMSS assesses level of consciousness from 0
(awake and alert) to 4 (unarousable). The SBS has six levels
from 3 (unresponsive) to +2 (agitated). Another one-
item scale, the Ramsay scale, has been used mainly for
adults and is not applicable to preverbal children as it
includes an item ‘responds to commands only’.[10,11] To
date, the Richmond Agitation–Sedation Scale (RASS)[12] is
more often used in adults, but it has not been validated for
children as this includes the item ‘overtly combative or vio-
lent; immediate danger to staff’.
An example of a scale that includes several behavioural
indicators of distress is the COMFORT behavioural (COM-
FORT-B) scale.[10] The COMFORT-B scale can be used
both in ventilated and spontaneously breathing patients
and has proven to be valid for both pain and sedation
assessment. In addition, the scale is able to detect treat-
ment-related changes in pain or distress intensity and
therefore can reliably guide pain and sedation manage-
ment.[13] Still, the COMFORT-B scale cannot be applied in
patients with fluctuations in neurological status, pre-exist-
ing neurological disorders or patients receiving neuromus-
cular blocking agents.
A limitation of behavioural assessment tools in general is
the difficulty to discriminate between pain, discomfort,
withdrawal symptoms or delirium. For example, the Face,
Legs, Activity, Cry and Consolability (FLACC) scale, one of
the most widely used pain assessment scales, was found
wanting in its capacity to discriminate pain and distress.[14]
For a decade, the Bispectral Index Monitor (BIS) was
considered promising for objective assessment of sedation.
Studies comparing BIS to the COMFORT (or COMFORT-
B) scale[15–22] showed correlations ranging from weak[15] to
excellent when grouped in a BIS range of 41–60.[17] This
wide variation can be partially explained by different study
conditions, as the weak correlation was found in patients
undergoing endotracheal suctioning, and the high correla-
tion was found during continuous sedation. Depending on
the clinical indication, BIS can potentially be used,
although it has not proven valid for children under the age
of 1 year old as the EEG algorithm has not been validated
in infants.[23]
Prolonged administration of sedatives may lead to drug
tolerance and physical dependency, leading to iatrogenic
withdrawal syndrome after abrupt discontinuation or (too
rapidly) tapering down of these drugs. The symptoms of
this syndrome overlap with signs of undersedation. The
Withdrawal Assessment Tool-1 (WAT-1) and the Sophia
Observation withdrawal Symptoms score (SOS) are the
most valid and reliable tools to identify withdrawal in
the PICU.[24,25] Furthermore, a position statement from
the European Society for Paediatric And Neonatal Intensive
Care (ESPNIC) provides clinical recommendations for
sedation and withdrawal syndrome assessment in the
paediatric age group.[26]
Sedation Guidelines
Sedation management in adults has shifted from full
unconscious sedation to a more easily arousable state.[27]
In this approach, the use of sedation guidelines and pro-
tocols was associated with reduced ICU and hospital
length of stay (LOS) as well as reduced duration of
mechanical ventilation (MV).[28] In paediatrics, however,
a systematic review published in 2013[29] showed that
some studies also found a reduced ICU LOS and dura-
tion of MV in protocolized sedation arms, but concluded
that the overall evidence for protocolized sedation
remained relatively poor due to the low quality of stud-
ies. Children’s cognition and behaviour clearly require a
different strategy.
One year later, Curley et al.[30] reported on the largest
multicentre RCT comparing protocolized sedation with
physician-driven usual care in a mixed PICU population.
The protocolized sedation management had not resulted,
however, in shorter MV duration or ICU and hospital LOS.
Heterogeneity in outcome measures and pharmacological
agents makes it difficult to obtain sufficient evidence for
the usefulness of sedation guidelines in paediatric intensive
care. A systematic review of Vet et al.[31] concluded that
optimal sedation is achieved in only around 60% of
Table 1 Continued
Study
Sample size
and age Design Outcome
Parkinson et al.[107] N = 44, 0–15 years Randomized controlled trial of midazolam IV
vs chloral hydrate and promethazine PO
More optimal sedation in chloral
hydrate/promethazine group,
1 patient with indication of
delirium in chloral
hydrate/promethazine group
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sedation assessments and that oversedation is more com-
mon than undersedation. Oversedation often was not ade-
quately managed by tapering off medication, indicating
that healthcare professionals may be tolerating overseda-
tion. This attitude may diminish the effect of protocolized
sedation in trials. It would seem that ‘protocolized’ does
not automatically mean ‘uniformity’ or ‘one size fits all’.[32]
In adults, the method of daily sedation interruption
(DSI) seemed promising in reducing ICU LOS and MV
duration,[33,34] but conclusive evidence has not yet been
found.[35,36] A multicentre RCT comparing protocolized
sedation and DSI plus protocolized sedation in the PICU
showed no beneficial effects of DSI,[37] in contrast to two
other RCTs in children.[38,39] Vet et al. compared to proto-
colized sedation management instead of physician-based
sedation management, which may imply a positive effect of
the protocolized sedation in the control arm.
Although an optimal level of sedation often cannot be
achieved without pharmacological treatment it is also
important to consider environmental factors and non-
pharmacological interventions. Light and noise, for exam-
ple, can be disturbing, and care should be taken to let the
children wear ear plugs, ask staff to speak softly and prevent
ongoing alarm sounds, etc. Non-pharmacological interven-
tions to reduce stress, such as live or recorded music, have
been primarily studied in adult critical care.[40] A meta-
analysis including three RCTs of music therapy offered to
paediatric surgical patients (0–18 years), although not in
the intensive care setting, reported significant reduction in
pain, anxiety and distress.[41] It would be worthwhile to
study non-pharmacological interventions in the PICU
setting.
Pharmacological Aspects
Several overviews of commonly used sedatives have already
been published.[42–44] Still, the dosing regimens greatly dif-
fer. This is not surprising, as most of these sedatives are
prescribed off-label.[2] Figure 1 illustrates the mechanisms
of actions of the different sedatives. Table 2 provides PK
and PD properties of the most common sedatives including
proposed dosing strategies.
Low-volume blood collection techniques such as dry
blood spot sampling[45] in combination with new analysis
techniques such as LC-MS/MS, for which less blood is
needed, could help establish optimal paediatric dosing
strategies by enhancing pharmacokinetic research. More-
over, comparative effectiveness studies and population PK-
PD studies using opportunistic and sparse sampling could
further facilitate paediatric drug research.[46]
However, many internal and external factors can alter
the PK and PD of sedative drugs. The internal factors
include critical illness itself, which has been correlated with
altered PK parameters of midazolam[47,48] and other
drugs,[49] decreased cardiac output, changes in liver and
kidney function and altered distribution, for example, in
children with burns.[50] External factors include renal
replacement therapy,[51] ECMO[52,53] and hypother-
mia.[52,54] Increasingly, physiology-based pharmacokinetic
(PBPK) studies will offer the opportunity to integrate phys-
iological and pathophysiological changes over time in the
drug dosing schedules.
Furthermore, weight-based infusion concentrations are
often inaccurate. In a prospective study, 65% of opiate con-
centrations in a PICU and NICU differed >10% from the
Figure 1 An overview of the sites of action of the most commonly used sedatives in the pediatric intensive care unit.
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prescribed concentration.[55] This confounder should be
taken into account in PK-PD studies, and it should be con-
sidered to measure the actual administered infusion con-
centration.
Not only PK but also PD may be affected by critical ill-
ness. An adult study[56] found a significant correlation
between disease severity and level of sedation, independent
of propofol clearance. It is plausible that this holds also for
children.
Pharmacological Agents
Benzodiazepines
Benzodiazepines are the drug class of first choice, often in
combination with opioids. An exception must be made,
however, for the premature population as a study showed
that midazolam was associated with a higher incidence of
intraventricular haemorrhage grade III or IV and periven-
tricular leucomalacia compared to morphine.[57] Benzodi-
azepines have been used for sedation of mechanically
ventilated children for many years. The exact mechanism of
action is not yet clear, although it is known that all agents
from this class share the same site of action. Binding to this
site increases the frequency at which the chloride channel is
opened by c-amino butyric acid (GABA), thereby making
the neuron more sensitive to GABA. The more chloride is
allowed to enter the target neuron, the more it is hyperpo-
larized, resulting in a decrease in firing rate of this target
neuron. This in turn leads to the pharmacological effects of
benzodiazepines: sedation, anxiolysis and muscle relax-
ation.[58] This inhibitory effect of the GABA system is
developing during the first weeks of life; therefore, GABA-
ergic agents may be less effective in prematurely born and
term born neonates and may even lead to paradoxical reac-
tions such as increased agitation and convulsions.[59]
Midazolam
Midazolam is recommended in UK PICU guidelines as
first-choice sedative in most critically ill children. With
onset of action occurring within 1–5 min after infusion, its
effects last for 30–120 min after a single infusion, and even
up to 48 h after one week of continuous infusion.[60]
Besides sedation and anxiolysis, midazolam also provides
anterograde amnesia, thus minimizing children’s recall of
unpleasant experiences after a PICU admission.[61] Midazo-
lam is mainly metabolized to the equipotent metabolite 1-
OH-midazolam and then glucuronidated to the renally
excreted 1-OH-MDZ-glucuronide.
Although a clear PK-PD relationship was not found in a
prospective study in 21 PICU patients, effective sedation
was achieved within the recommended range.[62]
Midazolam dosing can be effectively and simply titrated
based on level of sedation. However, as 80% of conjugated
1-OH-midazolam is eliminated renally, accumulation of
the metabolites may lead to prolonged sedation in children
with renal failure.[63] Furthermore, the sedation strategy for
a patient with severe sepsis should take into account that
critical illness reduces midazolam clearance independently
of serum creatinine levels and could increase sedation
depth. Critical illness thus leads to a great variability in
midazolam clearance, as was confirmed in a systematic
review.[64] It should be clear that this variability greatly
affects correct dosing. Ongoing midazolam trials in paedi-
atric long-term sedation or pharmacology are listed in
Table 3.
Lorazepam
The longer acting benzodiazepine lorazepam is used much
less than midazolam in the PICU but has been included in
the Best Pharmaceuticals for Children Act (BPCA) Priority
List.[30,65] Its IV formulation contains propylene glycol
(PG), which at toxic amounts can lead to lactic acido-
sis.[43,66] Note should be taken that the PG metabolism is
immature in preterm and term neonates.[67,68] It is recom-
mended to carefully monitor the osmol gap.[69] Data on a
PK-PD relationship of lorazepam for sedation are lacking.
Pharmacokinetics are well-described in children with sei-
zures and status epilepticus[70–72] and a PBPK model
underscores the low elimination rate in neonates and the
higher elimination rate in children around 2 years of
age.[73] Still, a clear evidence-based dosing regimen for
critically ill children is not yet available (see Table 3 for
ongoing paediatric lorazepam studies).
Alpha-2-adrenergic receptor agonists
If benzodiazepines fail to achieve adequate sedation, adjuncts
such as the a2-receptor agonists clonidine and dexmedeto-
midine can be used, which nevertheless are not labelled for
this indication. Α2-receptor agonists reduce sympathetic out-
flow[74] by stimulating presynaptic a2-adrenergic receptors,
thereby reducing the noradrenaline release into the synapse.
This provides sedation without respiratory depression.
Because of its analgesic properties, clonidine is often given as
spinal anaesthesia adjunct after surgical procedures.[75]
Dexmedetomidine could reduce MV duration and ICU
LOS[76] when compared to standard sedation practices, but
there is still limited experience with this sedative. In critically
ill children, both clonidine and dexmedetomidine exert
effects on the cardiovascular system, the latter theoretically to
a lesser extent, as this is a more a2-selective agonist. How-
ever, both seem to be well-tolerated and the cardiovascular
side effects are well-manageable.[77–79]
© 2016 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, 69 (2017), pp. 498–513 503
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Clonidine
Clonidine has a relatively long half-life,[80] and therefore, it is
recommended to give a loading dose before a continuous
infusion. Only one published trial in children, the SLEEPS
study, did use a loading dose[81]; whereas in other trials, a
loading dose was not applied.[82–84] This practice could lead
to a later onset of action of clonidine.[80]
The SLEEPS study compared clonidine to midazolam
and found no significant difference in efficacy. The study
was underpowered, however, as recruitment appeared
problematic, and true non-inferiority of clonidine therefore
was not shown. Genuine PK-PD research has not been per-
formed, but adequate sedation could be reached with a
plasma level of 0.9–2.5 ng/ml.[83] PK-PD simulations[80]
have shown that this level is reached in the majority of
patients receiving 1 mcg/kg per h, but without the use of a
bolus dose, it will take up to at least 24 h to reach this level.
Dosing recommendations are still not evidence-based, but
evidence is gained from an ongoing RCT (the CloSed trial:
NCT02509273 on clinicaltrials.gov).
Dexmedetomidine
Dexmedetomidine seems to reduce cardiovascular complica-
tions after cardiac surgery.[85] A beneficial effect was found in
a meta-analysis[86] of haemodynamic outcomes in children
after surgery for congenital heart disease. Three RCTs on
dexmedetomidine in children[87–89] showed a decrease in MV
duration and an opioid-sparing effect. Many of the children
in these trials had bradycardia, but this had no effect on
blood pressure. Optimal dosing of dexmedetomidine is
unknown. Its clearance is immature during the first 2 years
of life, then increases to above adult level when expressed per
kg bodyweight and returns to adult levels after 5 years of
age.[90] The half-life in preterm neonates is twice that in term
neonates.[91] A PK-PD model has been established only for
children after cardiac surgery.[92] A target plasma level of
0.6 mcg/l is regarded effective in adults,[93] but a target
plasma level for children is unknown. Simulation of doses
used in trials based on a pooled population PK analysis[90]
estimates the target plasma level to lie between 0.4 and
0.8 mcg/l, but this needs to be confirmed in a larger patient
group. Moreover, experience with dexmedetomidine in chil-
dren is relatively scarce so knowledge on safety is also lacking.
Nevertheless, several paediatric studies on dexmedetomidine
are underway (see Table 3).
Other sedative agents
Propofol
Propofol is a very rapid-acting and versatile sedative. It is
included in the revised priority list of the EMA,[94] forT
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procedural sedation in the neonatal age group. While often
used as sedative in adult ICUs,[95] its long-term use in chil-
dren is contraindicated as it may lead to a propofol infu-
sion syndrome (PRIS), a metabolic disorder with severe
metabolic acidosis, hyperkalaemia, hyperlipidemia, rhab-
domyolysis and organ failure, associated with an increased
risk of mortality.[60] A fatty acid oxidation disturbance may
be the underlying aetiology. Risk factors are doses >4 mg/
kg per h with a duration of >48 h, but short-term high
doses can be dangerous, too. Other risk factors include a
young age, critical illness, high fat and low carbohydrate
intake, inborn errors of mitochondrial fatty acid oxidation
and concomitant catecholamine infusion or steroid ther-
apy.[96] Wang et al.[97] pooled seven paediatric pharma-
cokinetic studies and evaluated the allometric exponent of
0.75, which is often used to estimate the clearance in indi-
viduals of different age. The models gave a clear insight into
the PK of propofol in all age groups. Propofol PD is less
well-studied. One study found a PK-PD relation[98] with a
wide variability in the PD endpoint, for which reason the
authors advise dose titration. Four propofol PK-PD trials
are being performed (Table 3).
Ketamine
Ketamine is a NMDA receptor-blocking agent, which pro-
vides dissociative anaesthesia[99] ‘disconnecting’ the thala-
mocortical and limbic systems, that is disconnecting the
CNS from outside stimuli.[100] Ketamine preserves the res-
piratory drive and the blood pressure and is thus suitable
for use in haemodynamically unstable patients.[101] It stim-
ulates the release of endogenous catecholamines, producing
dose-dependent tachycardia and hypertension. This mecha-
nism is also used in refractory bronchospastic events.[102]
Ketamine is contraindicated for patients with a raised
intracranial pressure as ketamine may further increase the
pressure by intracerebral vasodilation. The blocking of the
NMDA receptor may prevent opioid tolerance; therefore,
ketamine often serves as an adjunct to sedatives and opioid
analgesics, with an opioid-sparing effect.[43,103] Ketamine is
available as the racemic mixture of R() and S(+) keta-
mine, but the S(+) enantiomer is twice as potent as racemic
ketamine and has fewer side effects.[104] Some European
countries have consequently replaced the racemic mixture
with S(+) ketamine (esketamine). A PD profile of ketamine
has been established in children in an emergency depart-
ment setting where short-term sedation and analgesia were
required for brief painful procedures.[105] The profile shows
that a target serum concentration of 1 mg/l provides mod-
erate sedation and that a concentration of 1.5 mg/l provides
deep sedation. However, optimal dosing should still be con-
firmed by a well-designed RCT with adequate long-term
sedation as endpoint (for ongoing PK studies, see Table 3).
Chloral hydrate
Chloral hydrate (CH) is a prodrug, rapidly converted by
acetaldehyde dehydrogenase to the active metabolite tri-
chloroethanol (TCE), which is either glucuronidated to an
inactive metabolite, or oxidized to trichloroacetic acid
(TCA) and then excreted by the kidneys.[106] One trial
showed better sedation using chloral hydrate with promet-
hazine compared to midazolam intravenously in critically
ill children who tolerated nasogastric feeding.[107] However,
enteral sedatives are not recommended primarily in this
population as the enteral absorption is unpredictable.[108]
Plasma levels of CH could be detected after hours in neo-
nates, while in healthy adults, the half-life is very short.[109]
A correlation was also found between CH plasma levels and
sedation scores, although TCE is the presumed active
metabolite. As it is unclear which of the compounds, CH or
TCE, provides sedation, pharmacokinetic data are difficult
to interpret, and thus, an evidence-based dosing recom-
mendation is lacking.[110] Moreover, neonates may be vul-
nerable to toxic levels of TCE and TCA because these
metabolites have a longer half-life at neonatal age.[111]
Chloral hydrate has been associated with a higher incidence
of bradycardiac events in prematurely born neonates, which
implies that cardiorespiratory monitoring is needed.[112]
Future research should be aimed at the efficacy and safety
of CH in long-term sedation, preferably by establishing a
good PK-PD profile in different age groups. No trials
involving CH have been registered yet.
Barbiturates
Pentobarbital
Pentobarbital (pentobarbitone) can provide profound
sedation when other first-line therapies fail. Doses are
titrated based upon a clear pharmacodynamic endpoint,
that is burst suppression on the EEG. However, BIS moni-
toring, which is easier to perform, could be a valid alterna-
tive to EEG monitoring in this indication.[113] BIS
monitoring is validated only for children older than 1 year
and also has its limitations when used in critical care. For
example, BIS is usually recorded on one side of the brain,
while asymmetrical intracranial pathology may be pre-
sent.[114] As the cerebral oxygen demand is reduced, the
cerebral blood flow is reduced as well and consequently the
intracranial pressure will fall.[115] Pentobarbital is a rela-
tively short-acting barbiturate.[116] It is a very efficient
sedative, but has been associated with adverse effects[117]
such as hypotension (as it is a direct negative inotrope),
oversedation, choreo-athetoid neuromuscular phenomena
and withdrawal. The drug may suppress the immune sys-
tem, which effect could be relevant to critically ill children
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with multiple accesses to the blood stream.[118] Its PK and
PD have been well-established in adults, but data in chil-
dren are limited. A population PK study in children after
open heart surgery suggested that younger infants would
need a relatively higher dose based on body weight due to
increased clearance.[92] However, in this study, no link was
made to a PD endpoint, so it remains unclear whether
dosages should be adapted as there is a clear clinical titra-
tion endpoint.
Thiopental
Thiopental (thiopentone) is an ultra-short-acting barbitu-
rate with an onset of action of 20–40 s after intravenous
infusion.[119] It is widely used as an anaesthesia induction
agent. Like pentobarbital, thiopental is a suitable agent for
patients with raised intracranial pressure. PK and PD stud-
ies have been rarely performed in children, and most of
them date from the 1980s.[120–123] Despite a reported dou-
ble clearance compared to adults,[121] doses do not need to
be doubled.[119] Thiopental dose requirement varies among
individuals, and titration to the burst suppression EEG pat-
tern should take place, along with careful therapeutic drug
monitoring.[124,125] Effective plasma levels vary between 15
and 35 mg/l (see Table 2 for a proposed dosing strategy).
Discussion
This review shows an increasing interest in research on
PICU sedation pharmacotherapy. Still, there is a lack of
well-designed studies and consequently many practices are
not yet evidence based. This type of research is complicated
by different methods of sedation assessment, different
pharmacokinetics in different age and weight categories,
patient heterogeneity with multiple factors influencing the
pharmacokinetics and also by ethical and practical consid-
erations. For ethical reasons, drug studies cannot be per-
formed in healthy children, which implies that illness
severity will always be a confounding factor. On the other
hand, for PICU practice, we only need information on
critically ill children, and there should be always dealt with
different severities of illness.
Traditional RCTs come with limitations as well. Results
often apply only to a selective study population based on
strict inclusion and exclusion criteria for the sake of inter-
nal validity. External validity is compromised; however,
thus, pragmatic RCTs or cohort studies and well-designed
titration studies with an objective and clear PD endpoint
should complement classical RCT designs.[126] Moreover,
using a classical RCT design with placebo as comparator is
unethical in sedation research as then the control group
may suffer profound anxiety and agitation. When it comes
to safety, children should be followed for decades after drug
exposure as long-term effects are important endpoints as
well.[127]
PK-PD modelling might overcome several practical
issues in paediatric drug research. While in the standard
two-stage approach, individual values play a central role in
determining PK parameters, and therefore, large patient
samples are needed; the nonlinear mixed-effects models
(NONMEM) approach provides a Bayesian-based predic-
tion of PK parameters using population data.[128] This
approach resulted in a new dosing regimen for morphine
in infants[129] with much lower dosing than generally
recommended so far, suggesting that neonates have been
universally overdosed.
Improvements may also be made in the field of quantify-
ing pharmacodynamics. A study in which the item response
theory was applied to the COMFORT scale and the Prema-
ture Infant Pain Profile (PIPP) score made clear that the
behavioural items corresponded better with pain and dis-
comfort than did the physiological items.[130] A previous
study has already made clear that the physiological items in
the COMFORT scale have no added value,[10] but the item
response theory with its more advanced statistical tech-
niques allows calculating the probability of pain for each
item. Thus, when using assessment scales consist of more
than one item, it would be worthwhile to collect data on
each of the items rather than the total score only.
Another form of in silico experiments are PBPK
models[73,131] representing a multicompartment model
applicable to multiple drugs. Pharmacodynamics can be
linked to such models by adding biophase concentrations,
but only a few full PBPK-PD models have been developed
so far for the administration of midazolam, theophylline,
lorazepam and propofol to children.[73,132,133] The validity
of these models should be evaluated further. As sedatives
act on the CNS, evaluation requires obtaining brain tissue
concentrations, which is not possible in routine critical
care. Experimental strategies include calculations based on
mass balance principles using the net flux of drugs (ob-
tained from arterial and venous concentration differ-
ences)[134] or microdialysis.[135] Both strategies are invasive
and therefore subject to practical objections and ethical
considerations.
Future Perspectives
Apart from optimal dosing strategies, new products may
also improve pharmacological sedation management. A
promising example is the ultra-rapid-acting benzodiazepine
remimazolam,[136] which has a pharmacokinetic profile
comparable to that of remifentanil, allowing for fast titra-
tion. It has only been studied in adults so far.
Monotherapy with remifentanil was found effective for
long-term ICU sedation in adults.[137] In a paediatric study,
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remifentanil was as effective as fentanyl for sedation and
analgesia and allowed for earlier extubation.[138] However,
its use carries the risk of opioid-induced hyperalgesia
(OIH) that is a phenomenon seen after opioid administra-
tion,[139] notably on account of its short half-life and fast
onset of action.[140,141] It has been suggested that ketamine
or clonidine as adjuvants could prevent the OIH,[142] but
these agents may have unwanted side effects. Gradual
remifentanil withdrawal has been suggested as well, but
OIH was still observed after cold pressure testing in one
study.[143] Moreover, chronic pain may develop after (pro-
longed) surgery,[144] so more data on these issues are war-
ranted before it is regularly used in children.
In adult intensive care, volatile agents such as sevoflu-
rane, desflurane and isoflurane have a favourable pharma-
cological profile with short elimination half-lives and low
toxicity and could be suitable for long-term sedation.[145]
These agents have not been studied in children so far. There
is some concern that they may have adverse long-term neu-
rological effects,[146–148] so more conclusive studies on the
long-term effects of these agents are needed before efficacy
trials may be performed.
Conclusion
A variety of sedatives are used in the paediatric intensive care
unit, but evidence and pharmacokinetic data are still scarce.
Fortunately, there is an active research scene which yields
promising new PK and PD data using new study designs
combined with advanced laboratory methods and modelling.
However, pharmacology is not the only way that can lead to
improved paediatric sedation management. We recommend
that future research focuses also on sedation assessment and
implementation strategies of protocolized sedation.
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